Clinical Laboratory Tests Market Analysis Report By Type (CBC, HGB/HCT, BMP, HbA1c Testing, Electrolyte Testing, Liver Panel), By End Use (Primary Clinics, Central Labs), And Segment Forecasts, 2019 - 2026

Industry Insights

The global clinical laboratory tests market size was valued at USD 165.48 billion in 2018. It is expected to expand at a CAGR of 7.1% during the forecast period. Rise in prevalence of chronic disorders along with heightened awareness among health-conscious people has encouraged the growth of the market. 

Increasing investments in epidemiology of target diseases such as diabetes and cardiovascular disorders are estimated to drive the market over the forecast period. According to an article published by WHO in 2018, diabetes was the direct cause of around 1.6 million deaths in 2016.

Growing geriatric population is anticipated to propel the market. According to the Department of Economic and Social Affairs, in 2017, the population aged 60 years and above was 962.3 million and is projected to reach around 2080.5 million by 2025.

Rising frequency of consumption of unhealthy food, insufficient exercise, along with rising obesity are responsible for increase in incidence of chronic diseases. In addition, rising awareness about necessity of regular body profiling among patients and healthcare professionals is poised to enhance the usage of clinical tests.

Increasing adoption of laboratory automation systems is likely to boost the growth of the market over the forecast period. For instance, according to an article published by the American Association for Clinical Chemistry, more than 30.0% of the laboratories inJapan, North America and Europe have implemented laboratory automation. Various benefits associated with implementation of automation such as its ability to reduce errors along with improving efficacy can to augment the overall market.

End-use Insights

Based on end use, the global clinical laboratory tests market has been bifurcated into central laboratories and primary clinics. Central laboratories dominated the market in 2018. Presence of various central laboratories such as Q² Solutions, Pharmaceutical Product Development, LLC, Phoenix Lab, Covance Inc., CIRION BioPharma Research Inc., and Eurofins Scientific has been contributing to the growth of the segment.

The primary clinics segment will, however, register a higher CAGR of 7.6% owing to surging demand for rapid test results. Rising awareness among physicians and patients regarding testing in-clinics is anticipated to spur the growth of the overall market over the forecast period. Introduction of rapid and portable type of analyzers is a key technology advancement, which can supplement the growth of the segment.

Type Insights

On the basis of type, the market has been segmented into Basic Metabolic Panel (BMP), Complete Blood Count (CBC), HbA1c tests, HGB/HCT tests, comprehensive metabolic panel tests, BUN creatinine tests, renal panel tests, electrolytes testing, liver panel tests, and lipid panel tests.

Basic metabolic tests accounted for a sizeable share in the market in 2018 owing to growing prevalence of lifestyle-induced diseases, such as obesity and metabolic abnormalities. Lipid panel tests were expected to be the fastest growing segment over the forecast period due to increasing focus on epidemiology of cardiovascular disorders and diabetes.

According to an article published by the World Health Organization, more than 17 million people die from cardiovascular disorders annually due to unhealthy behaviors, high blood pressure, and high blood cholesterol contents.

The liver panel market has been further divided into hepatitis, liver cirrhosis, liver cancer, bile duct obstruction, bone disease, and autoimmune disorders. Hepatitis was the largest segment in 2018, whereas liver cirrhosis was the fastest growing segment owing to increasing lifestyle disorders and growing consumption of alcohol and tobacco.

Regional Insights

North America held the largest revenue share in the market in 2018. Strong presence of test volumes and increasing penetration of advanced diagnostic technologies are projected to support the dominance of the regional market. Widening base of geriatric population, rising prevalence of cancer, and high penetration of technologically advanced diagnostic techniques are poised to augment the market over the coming years.

Asia Pacific is likely to be most promising destination for market players owing to improving healthcare infrastructure supporting implementation of advanced diagnostic technologies in emerging markets of India and China. Presence of huge untapped opportunities in the form of unmet medical needs, increasing avenues of scientific research, and positive economic growth are some of the primary growth stimulants for the market.

Clinical Laboratory Tests Market Share Insights

Some of the key players are Laboratory Corporation of America Holdings; Charles River; OPKO Health, Inc.; Sonic Healthcare;NeoGenomics Laboratories Inc.; Healthscope;Labco; Qiagen; ARUP Laboratories; Quest Diagnostics Incorporated; Siemens Healthcare GmbH; Fresenius Medical Care; Merck KgaA; Tulip Diagnostics (P) Ltd; Bioscientia Institute for Medical Diagnostics GmbH; and Abbott.

These key players are majorly focusing on mergers and acquisitions along with strategic partnership. For instance, in 2018, Charles River acquired MPI research, a premier non-clinical contract research organization providing comprehensive testing services to medical devices and biopharmaceutical companies. The acquisition will enhance the ability of Charles River to achieve long-term goals by expanding biotechnology client base.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional and country levels and provides an analysis of the industry trends in each of the sub-segments from 2013 to 2026. For the purpose of this study, Grand View Research has segmented the global clinical laboratory tests market report on the basis of type, end use, and region:

• Type Outlook (Revenue, USD Billion, 2013 - 2026)

  • Complete Blood Count

  • HGB/HCT

  • Basic Metabolic Panel

  • BUN Creatinine Tests

  • Electrolytes Testing

  • HbA1c Tests

  • Comprehensive Metabolic Panel

  • Liver Panel

    • Hepatitis

    • Bile Duct Obstruction

    • Liver Cirrhosis

    • Liver Cancer

    • Bone disease

    • Autoimmune Disorders

    • Others

  • Renal Panel

  • Lipid Panel

• End-use Outlook (Revenue, USD Billion, 2013 - 2026)

  • Central Laboratories

    • Complete Blood Count

    • HGB/HCT

    • Basic Metabolic Panel

    • BUN Creatinine Tests

    • Electrolytes Testing

    • HbA1c Tests

    • Comprehensive Metabolic Panel

    • Liver Panel

    • Renal Panel

    • Lipid Panel

  • Primary Clinics

    • Complete Blood Count

    • HGB/HCT

    • Basic Metabolic Panel

    • BUN Creatinine Tests

    • Electrolytes Testing

    • HbA1c Tests

    • Comprehensive Metabolic Panel

    • Liver Panel

    • Renal Panel

    • Lipid Panel

• Regional Outlook (Revenue, USD Billion, 2013 - 2026)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • U.A.E.

    • Saudi Arabia